Wegovy can cut heart attack, stroke risk; Novo Nordisk stock soars

A study conducted by Novo Nordisk (NVO) shows that the drugmaker's obesity drug Wegovy can slash the risk of serious heart problems, like heart attacks and strokes, by up to 20 percent. Yahoo Finance Health Care Reporter Anjalee Khemlani explains the study's findings, comparing Wegovy to other pharmaceutical developers' weight-loss drugs.